Efficacy and Safety of Remimazolam Besylate Versus Propofol During Hysteroscopy

Single-centre Randomized Controlled Trial

Xiaoqiang Zhang; Shuang Li and Jing Liu

Disclosures

BMC Anesthesiol. 2021;21(156) 

In This Article

Background

Hysteroscopy is one of the most common outpatient procedures in the diagnosis and treatment of endometrial and other intrauterine diseases. Most patients require anaesthetic intervention because they cannot tolerate the intense pain of cervical dilatation and endometrial curettage.[1–3]

The commonly used anesthetic methods used for hysteroscopic surgery include propofol combined with opioids, propofol combined with dexmedetomidine, paracervical block, and local anaesthesia.[4–6] Among these, propofol combined with opioids is still the most commonly used method to control pain during hysteroscopy.[7] However, propofol has a high incidence of adverse events, such as injection pain, postoperative dizziness, and low pulse oximetry (SpO2).

Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times. It does not accumulate in tissues; metabolism is independent of liver and kidney function without any major side effect. Furthermore, opioids can have a sedative effect in some endoscopic examinations.[8–10]

This trial was conducted to confirm the efficacy and safety of remimazolam besylate versus propofol during hysteroscopy.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....